drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T cells)
drug_description
Autologous T cells genetically modified via lentiviral transduction to express a B7-H3–targeting chimeric antigen receptor with CD28/CD3ζ signaling domains and membrane 4-1BB ligand to enhance costimulation and persistence; administered locoregionally via CNS reservoir to treat B7-H3 (CD276)-positive pediatric CNS tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express a B7-H3-specific chimeric antigen receptor with CD28/CD3zeta signaling. Binding to B7-H3 (CD276) on tumor cells triggers T-cell activation, cytokine release, and cytotoxic killing. Coexpressed membrane 4-1BB ligand provides costimulation to enhance expansion and persistence. Administered locoregionally into the CNS for B7-H3-positive pediatric brain tumors.
drug_name
B7-H3-CAR T cells
nct_id_drug_ref
NCT05835687